Bangalore, May 7, 2008: Hyderabad’s Suven Life Sciences says the European Patent Office (EPO) has granted the Product Patent, EP 1581492 to its clinical candidate SUVN-502 that is valid until June 2023.

 

 "We are very pleased by the grant of this patent for our clinical candidate which is being developed for CNS disorders in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer’s disease (AD), Attention Deficit Hyperactivity Disorder (ADHD), memory impairment associated with aging and Schizophrenia etc, the unmet medical needs. Potential market opportunity for these indications is more than $18 billion globally. Granting of this patent to our clinical candidate SUVN-502 is more timely and relevant now that the candidate is entering into clinical trials. Securing patent protection for our discoveries enhanced the value of our technologies and products   substantially,” says Venkat Jasti CEO of Suven Life Sciences.

 

With EP 1581492, Suven has four European Product Patents granted and all of them have been validated in all the 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland.